Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
1,205
Views
3
CrossRef citations to date
0
Altmetric
Research Papers

Novel hydroxyl carboximates derived from β-elemene: design, synthesis and anti-tumour activities evaluation

Yuan Gaoa School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, China;e Institute of Chinese Materia Medical, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaView further author information
,
Nian-Dong Maoa School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, ChinaView further author information
,
Hao Chea School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, ChinaView further author information
,
Li Xua School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, ChinaView further author information
,
Renren Baia School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, ChinaCorrespondence[email protected]
View further author information
,
Li-Wei Wanga School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, ChinaCorrespondence[email protected]
View further author information
,
Xiang-Yang Yea School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3739-0930View further author information
ORCID Icon &
Tian Xiea School of Pharmacy, Hangzhou Normal University, Hangzhou, China;b Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China;c Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China;d Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou, China;e Institute of Chinese Materia Medical, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 2403-2416 | Received 27 Apr 2022, Accepted 21 Aug 2022, Published online: 06 Sep 2022

References

  • Cheng H, Ge X, Zhuo S, et al. β-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2. Front Pharmacol 2018;9:1413.
  • Wang X, Liu Z, Sui X, et al. Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: a meta-analysis following the PRISMA guidelines. Phytomedicine 2019;59:152787.
  • Barrero AF, Herrador MM, Quílez del Moral JF, et al. Efficient synthesis of the anticancer beta-elemene and other bioactive elemanes from sustainable germacrone. Org Biomol Chem 2011;9:1118–25.
  • Chen SL, You J, Wang GJ. Supercritical fluid extraction of β-elemene under lower pressure. Chin J Chromatogr 2001;19:179–181.
  • Li CL, Chang L, Guo L, et al. β-elemene induces caspase-dependent apoptosis in human glioma cells in vitro through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Asian Pac J Cancer Prev 2014;15:10407–12.
  • Liu J, Zhang Y, Qu J, et al. β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer 2011;11:183.
  • Min G, Ying L, Jian Z, et al. Beta-elemene inhibits cell proliferation by regulating the expression and activity of topoisomerases I and II[alpha] in human hepatocarcinoma HepG-2 cells. Biomed Res Int 2015;2015:153987.
  • Wang G, Li X, Huang F, et al. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 2005;62:881–93.
  • Tan G, Wang Z, Che L, et al. Immunotherapeutic effects on murine pancreatic carcinoma by beta-elemene combined with dendritic cells modified with genes encoding interleukin-23. Front Med China 2007;1:41–5.
  • Bai R, Jie X, Salgado E, et al. Rational design, synthesis and biological evaluation of novel derivatives based on in vivo metabolism of natural product β-elemene. Lett Drug Des Discov 2018;15:905–12.
  • Chen J, Duan W, Bai R, et al. Design, synthesis and antioxidant activity evaluation of novel β-elemene derivatives. Bioorg Med Chem Lett 2014;24:3407–11.
  • Liu G, Kong Z, Shen Y. Synthesis, characterization, and in vitro anti-proliferative activity of novel β-elemene monosubstituted derivatives. Med Chem Res 2013;22:3536–40.
  • Ren Y, Sun Y, Cheng K, et al. Synthesis and radiolabelling of Re(CO)3-β-elemene derivatives as potential therapeutic radiopharmaceuticals. J Label Compd Radiopharm 2009;52:139–45.
  • Sun Y, Liu G, Zhang Y, et al. Synthesis and in vitro anti-proliferative activity of β-elemene monosubstituted derivatives in HeLa cells mediated through arrest of cell cycle at the G1 phase. Bioorg Med Chem 2009;17:1118–24.
  • Yu Z, Wang R, Xu L, et al. β-Elemene piperazine derivatives induce apoptosis in human leukemia cells through downregulation of c-FLIP and generation of ROS. PLoS One 2011;6:e15843.
  • Yu Z, Wu F, Chen L, et al. ETME, a novel β-elemene derivative, synergizes with arsenic trioxide in inducing apoptosis and cell cycle arrest in hepatocarcinoma cells via a p53-dependent pathway. Acta Pharm Sin B 2014;4:424–9.
  • He X, Zhuo X-T, Gao Y, et al. β-Elemene derivatives produced from SeO2-mediated oxidation reaction. Royal Soc Open Sci 2020;7:200038.
  • Bai Z, Yao C, Zhu J, et al. Anti-tumor drug discovery based on natural product β-elemene: anti-tumor mechanisms and structural modification. Molecules 2021;26:1499.
  • Chen J, Wang R, Wang T, et al. Antioxidant properties of novel dimers derived from natural β-elemene through inhibiting H2O2-induced apoptosis. ACS Med Chem Lett 2017;8:443–8.
  • Chen J, Wang T, Xu S, et al. Novel hybrids of natural β-elemene bearing isopropanolamine moieties: Synthesis, enhanced anticancer profile, and improved aqueous solubility. Fitoterapia 2017;120:117–25.
  • Chen J, Wang T, Xu S, et al. Discovery of novel anti-tumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway. Eur J Med Chem 2017;135:414–23.
  • Bai R, Zhu J, Bai Z, et al. Second generation β-elemene nitric oxide derivatives with reasonable linkers: potential hybrids against malignant brain glioma. J Enzym Inhib Med Chem 2022;37:379–85.
  • Gao Y, Zhang H, Lirussi F, et al. Dual inhibitors of histone deacetylases and other cancer-related targets: a pharmacological perspective. Biochem Pharmacol 2020;182:114224.
  • He X, Li Z, Zhuo X-T, et al. Novel selective histone deacetylase 6 (HDAC6) inhibitors: a patent review (2016-2019). Recent Pat anti-Cancer Drug Dis 2020;15:32–48.
  • Xie T, Ye X, Li Z, et al. 2022. β-Elemene halide and preparation method thereof. CN 110683932 A.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.